Beta-cell Responsiveness to the Incretin Hormones (Aim1)
Contact
Description
The goal of the study extension is to see whether the incretin hormone GIP increases insulin secretion in individuals with CF and normal glucose tolerance compared to individuals without CF and normal glucose tolerance. This study includes 3 or 4 visits.
Eligibility and criteria
IRB Number:
13-010240
Eligible age range:
Clinical trial phase:
N/A
Official title:
Related specialties
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.